抗癌扶正方联合化疗治疗中晚期非小细胞肺癌近期疗效观察

The Observation of Short-term Curative Effect of Anti-Cancer Fuzheng Prescriptions on Treatment for the Patients with Middle to Advanced Stage Nonsmall Cell Lung Cancer

目的:观察抗癌扶正方联合化疗治疗中晚期非小细胞肺癌的近期疗效。方法:用抗癌扶正方联合“GP”或“NP”或“TP”化疗方案治疗中晚期非小细胞肺癌70例,与单纯化疗组40例进行对照。结果:治疗组和对照组有效率分别为37.1%和32.5%,无显著性差异(P>0.05);临床获益率分别为82.8%和65%,有显著性差异(P<0.05);治疗组比对照组生活质量明显提高(P<0.05);临床症状改善率分别为76%和50.2%,有显著性差异(P<0.05);治疗组治疗后白细胞下降较对照组要轻(P<0.01);血红蛋白、血小板下降比较,无差异(P>0.05),两组治疗后肿瘤相关抗原表达下降无显著性差异(P>0.05)。结论:抗癌扶正方联合化疗治疗中晚期非小细胞肺癌,可以改善临床症状,提高生活质量,毒性低,可耐受。

Objective ： To observe the short - term curative effect of anti - cancer Fuzheng proscriptions combined with chemotherapy for patients with middle to advanced stage primary nonsmall cell lung cancer （ NSCLC ）. Method Seventy eases of NSCLC patients were treated with anti - cancer fuzheng prescriptions combined with GP or NP or TP regimes, and 40 cases of NSCLC patients were treatment with chemotherapy alone as control group. Results ：The rate of response and clinical advantage was 37. 1% and 74. 2% in anti - cancer Fuzheng prescriptions combined with chemotherapy group, and 32.5% and 70% in control group respectively （ P 〉 0. 05 ）. The quality of life were significant differonce between observed group and control group （ P 〈 0. 05）. The clinical symptoms improvement in observed group and control group were 76% and 50.2% （ P 〈 0.05）. The decrease of white cells was lower in treatment group than that in control group （ P 〈 0. 05）. The decrease of Hb and plate was non significant difference in two groups. Both of the two groups, the expression of tumors antigen reduced after treatment （ P 〈 0.01 ）. Conclusion ： Anti - cancer Fuzheng prescriptions combined with chemotherapy for patients with middle to advanced stage primary nonsmall cell lung cancer （NSCLC） was able to improve the clinical symptoms, enhance the quality of life and the lower toxicity was tolerant.